Evidence map›Paper›PMID 39999769›Full record

ArticleHIV medicine2025

High-risk human papillomavirus prevalence and serostatus in a cohort of cisgender women and people with a cervix living with perinatally acquired HIV.

Merle Henderson, Dierdre Lyons, Simon Beddows, Miranda Cowen, Kavita Panwar, Corrina Wright, Jacquie Ujetz, Ellie Crook, Hasit Patel, David Smith and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in HIV medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Aging of adult lifetime survivors with perinatal HIV.Current opinion in HIV and AIDS · 2025
    Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Merle HendersonImperial College London, Department of Infectious Disease, Faculty of Medicine, London, UK.
Dierdre LyonsImperial College Healthcare NHS Trust, London, UK.
Simon BeddowsVirus Reference Department, Public Health Microbiology Division, UK Health Security Agency, London, UK.
Miranda CowenImperial College Healthcare NHS Trust, London, UK.
Kavita PanwarVirus Reference Department, Public Health Microbiology Division, UK Health Security Agency, London, UK.
Corrina WrightCervical Screening London, Health Services Laboratories, London, UK.
Jacquie UjetzImperial College London, Department of Infectious Disease, Faculty of Medicine, London, UK.
Ellie CrookImperial College Healthcare NHS Trust, London, UK.
Hasit PatelCervical Screening London, Health Services Laboratories, London, UK.
David SmithCervical Screening London, Health Services Laboratories, London, UK.
Caroline FosterImperial College London, Department of Infectious Disease, Faculty of Medicine, London, UK.ORCID https://orcid.org/0000-0001-8278-8564
Sarah FidlerImperial College London, Department of Infectious Disease, Faculty of Medicine, London, UK.
Tamara ElliottImperial College London, Department of Infectious Disease, Faculty of Medicine, London, UK.ORCID https://orcid.org/0000-0001-8232-9413

Funding

British HIV AssociationImperial Health CharityNIHR Imperial Biomedical Research Centre
6 · The paper itself

Abstract

objectivesHuman papillomavirus (HPV)-associated cervical cancer risk is greater in people with HIV, although this has been at least partially attenuated by antiretroviral medication, enhanced cervical screening and HPV vaccination. People with perinatally acquired HIV may remain at higher risk due to lifelong immunosuppression and potentially reduced vaccine effectiveness. In this study in people with a cervix with perinatally acquired HIV, we explored cervical high-risk HPV (hrHPV) prevalence and HPV serostatus.

methodsParticipants were recruited from a London HIV service between 2020 and 2022. Cervical samples from those sexually active were analysed for hrHPV (Cepheid GeneXpert) and cytology, and, if abnormal, a referral was made to colposcopy. Serum samples were tested for antibodies against HPV6/11/16/18/31/33/45/52/58. A self-reported questionnaire including HPV vaccination history was completed.

resultsFifty-seven people were recruited with a median age of 25 years (range 18-34). Of those providing a cervical sample, 15/47 (32%) were hrHPV-positive and 12/40 (30%) had abnormal cytology; 1/17 referred for colposcopy had CIN2 (6%); 7/15 (47%) with hrHPV were below the national screening age of 24.5 years (range 19-23), and 9/15 (60%) reported previous HPV vaccination. No vaccinated participants had hrHPV16/18. Of those vaccinated, 37/39 (95%) were seropositive for HPV16 and 30/39 (77%) for HPV18. Two vaccinated participants were seronegative for HPV16/18; both had detectable HIV viral loads and CD4 counts <200 cells/μL at recruitment.

conclusionIn this small observational study we identified a 32% prevalence of cervical hrHPV. Cervical screening and HPV vaccination remain vital in this group, with further data required to inform screening guidelines for this population.

Indexed as

Cervix UteriHIV InfectionsPapillomavirus InfectionsUterine Cervical NeoplasmsAdolescentAdultAntibodies, ViralFemaleHuman Papillomavirus VirusesHumansLondonPapillomaviridaePapillomavirus VaccinesPrevalenceSeroepidemiologic StudiesYoung AdultAntibodies, ViralPapillomavirus VaccinesHPV prevalenceHPV vaccinehuman papillomavirusperinatally acquired HIV

Identifiers

PMID39999769
PMCPMC12045151

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.